Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
Rhea-AI Summary
Cullinan Therapeutics (Nasdaq: CGEM) announced management participation in two investor conferences and an analyst/investor event at the 2025 ASH Annual Meeting.
CEO Nadim Ahmed and CMO Jeffrey Jones will appear in fireside chats at the Stifel Healthcare Conference in New York on Nov 11, 2025 at 3:20 p.m. ET and at the Guggenheim Healthcare Innovation Conference in Boston on Nov 12, 2025 at 8:00 a.m. ET. The company will host an in-person analyst and institutional investor event on Dec 8, 2025 at 8:00 p.m. ET in Orlando following the oral presentation of Phase 1 CLN-049 results in AML/MDS (Presentation ID 768).
Investors may register by emailing nsmith@cullinantx.com. Webcasts will be available on the company investor relations Events and Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CGEM gained 3.48%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $471M at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team will participate in two upcoming investor conferences and will host a company event at the 2025 American Society of Hematology (“ASH”) Annual Meeting in Orlando, FL.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York, NY on Tuesday, November 11, 2025, at 3:20 p.m. ET.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 8:00 a.m. ET.
- The Company will host an in-person event for analysts and institutional investors on Monday, December 8, at 8:00 p.m. ET, during the 2025 ASH Annual Meeting. The event will follow the oral presentation of results from the Phase 1 study of CLN-049 in patients with AML or MDS earlier that morning (Presentation ID 768). Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations (nsmith@cullinantx.com).
Webcasts of the fireside chats and the ASH event will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
When will Cullinan Therapeutics (CGEM) present Phase 1 CLN-049 results at ASH 2025?
How can investors attend Cullinan Therapeutics' (CGEM) ASH 2025 analyst event on Dec 8, 2025?
When are Cullinan Therapeutics (CGEM) fireside chats at Stifel and Guggenheim in November 2025?
Will Cullinan Therapeutics (CGEM) webcast its ASH and conference presentations?
Who will represent Cullinan Therapeutics (CGEM) in November 2025 investor events?
